Urinary Glucose Research Articles

Population-based prevalence of self-reported pediatric diabetes and screening for undiagnosed type 2 diabetes in Chinese children in years 2017–2019, a cross-sectional study

The worldwide geographical and temporal variation in the prevalence of diabetes represents a challenge, but also an opportunity for gaining etiological insights. Encompassing the bulk of East Asians, a large and distinct proportion of the world population, China can be a source of valuable epidemiological insights for diabetes, especially in early life, when pathophysiology begins. We carried out a nationwide, epidemiological survey of Prevalence and Risk of Obesity and Diabetes in Youth (PRODY) in China, from 2017 to 2019, to estimate the population-based prevalence of diagnosed pediatric diabetes and screen for undiagnosed pediatric type 2 diabetes (T2D). PRODY was a nation-wide, school population-based, cross-sectional, multicenter survey by questionnaire, fasting urine glucose test and simple oral glucose tolerance test (s-OGTT), among a total number of 193,801 general-population children and adolescents (covered a pediatric population of more than 96.8 million), aged 3-18, from twelve provinces across China. The prevalence of the self-reported pediatric diabetes, the proportion of subtypes, the crude prevalence of undiagnosed T2D and prediabetes in general juvenile population and the main risk factors of type 1 (T1D) and type 2 (T2D) diabetes had been analyzed in the study. The prevalence of all self-reported pediatric diabetes was estimated at 0.62/1000 (95% CI: 0.51-0.74), with T1D at 0.44/1000 (95% CI: 0.35-0.54) and T2D at 0.18/1000 (95% CI: 0.13-0.25). For undiagnosed T2D, the crude prevalence was almost ten-fold higher, at 1.59/1000, with an estimated extra 28.45/1000 of undiagnosed impaired glucose tolerance (IGT) and 53.74/1000 of undiagnosed impaired fasting glucose (IFG) by s-OGTT screening. Maternal diabetes history is the major risk factors for all subtypes of pediatric diabetes in China. The PRODY study provides the first population-based estimate of the prevalence of pediatric diabetes China and reveals a magnitude of the problem of undiagnosed pediatric T2D. We propose a practical screening strategy by s-OGTT to address this serious gap. The National Key Research and Development Programme of China, Key R&D Program of Zhejiang, the National Natural Science Foundation of China and the Zhejiang Provincial Key Disciplines of Medicine, Key R&D Program Projects in Zhejiang Province.

Evaluation of the Effect of an α-Adrenergic Blocker, a PPAR-γ Receptor Agonist, and a Glycemic Regulator on Chronic Kidney Disease in Diabetic Rats

Diabetic nephropathy (DN) is a globally widespread complication of diabetes mellitus (DM). Research indicates that pioglitazone and linagliptin mitigate the risk of DN by reducing inflammation, oxidative stress, and fibrosis. The role of tamsulosin in DN is less studied, but it may contribute to reducing oxidative stress and inflammatory responses. The protective effects of combining pioglitazone, linagliptin, and tamsulosin on the kidneys have scarcely been investigated. This study examines the individual and combined effects of these drugs on DN in Wistar rats. Diabetic rats were treated with tamsulosin, pioglitazone, and linagliptin for six weeks. We assessed food and water intake, estimated glomerular filtration rate (eGFR), histological markers, urea, creatinine, glucose, NF-κB, IL-1, IL-10, TGF-β, and Col-IV using immunofluorescence and qPCR. The DN group exhibited hyperglycaemia, reduced eGFR, and tissue damage. Tamsulosin and linagliptin improved eGFR, decreased urinary glucose, and repaired tissue damage. Pioglitazone and its combinations restored serum and urinary markers and reduced tissue damage. Linagliptin lowered serum creatinine and tissue injury. In conclusion, tamsulosin, linagliptin, and pioglitazone demonstrated renoprotective effects in DN.

Comparison Between SGLT2 Inhibitors and Lactation: Implications for Cardiometabolic Health in Parous Women.

Sodium-glucose cotransporter-2 (SGLT2) inhibition and lactation result in the excretion of large amounts of glucose in urine or milk and are associated with a lower risk of cardiovascular events. The respective mechanisms behind this association with cardiovascular protection are not clear. This review compares the contribution of noninsulin-mediated glucose transport during pharmacologic inhibition of SGLT2 with noninsulin-mediated glucose transport during lactation in terms of the implications for the cardiometabolic health of parous women. The search topics used to obtain information on SGLT2 inhibitors included mechanisms of action, atherosclerosis, and heart failure. The search topics used to obtain information on lactation included cardiovascular health and milk composition. Subsequent reference searches of retrieved articles were also used. Active treatment with SGLT2 inhibitors affects glucose and sodium transport in the kidneys and predominantly protects against hospitalization for heart failure soon after the onset of therapy. Active lactation stimulates glucose transport into the mammary gland and improves subclinical and clinical atherosclerotic vascular disease years after delivery. Both SGLT2 inhibitors and lactation have effects on a variety of glucose transporters. Several mechanisms have been proposed to explain the cardiometabolic benefits of SGLT2 inhibition and lactation. Learning from the similarities and differences between both processes will advance our understanding of cardiometabolic health for all people.

Physiological Response and Sports Injury Risk Relevant Biomechanics in Endurance Obstacle Course Races

Obstacle course races (OCR) have experienced significant growth in recent years, with millions of participants worldwide. However, there is limited research on the specific physiological demands and injury prevention strategies required for these events. This study aimed to analyze the physiological responses and injury risks in participants of a 5 km (Sprint) and 13 km (Super) OCR. Sixty-eight participants were assessed for cortical arousal, leg strength, isometric handgrip strength, blood lactate, heart rate, blood oxygen saturation, body temperature, urine composition, spirometry values, hamstring flexibility, lower limb stability, foot biomechanics, and scapular kinematics, one hour before and immediately after the races. The results showed a significant decrease in leg strength (Sprint: r = −0.56, p < 0.01; Super: r = −0.54, p = 0.01) and urine pH (Sprint: r = −0.70, p = 0.03; Super: r = −0.67, p = 0.01) in both distances, with increases in urine colour, protein, and glucose (Sprint: p < 0.04). In the 13 km race, lower limb stability decreased significantly post-race (r = −0.53, p = 0.01). Positive correlations were found between performance and pre-race handgrip strength (Sprint: r = 0.71, p = 0.001; Super: r = 0.72, p = 0.01) and spirometry values (FVC, FEF 25–75%, FEV1) (Sprint: r = 0.52, p = 0.031; Super: r = 0.48, p = 0.035). Thermoregulation capacity, reflected in a higher pre-race body temperature and lower post-race body temperature, also correlated with improved performance (r = 0.49, p = 0.046). Injury risk increased post-race, with a significant decline in lower limb stability (p < 0.05). These findings highlight the importance of targeted training programs, focusing on grip strength, leg strength, respiratory muscle training, and hydration strategies to optimize performance and reduce injury risk in OCR athletes.

Model-based meta-analysis of HbA1c reduction across SGLT2 inhibitors using dose adjusted by urinary glucose excretion

This study was aimed to evaluate whether the dose–response relationship of the sodium glucose co-transporter-2 inhibitors (SGLT2is) in patients with type 2 diabetes mellitus (T2DM)—canagliflozin, dapagliflozin, empagliflozin, ipragliflozin, luseogliflozin, and tofogliflozin—can be explained in a unified manner based on their ability to promote urinary glucose excretion (UGE). Information on HbA1c reduction at various doses of each SGLT2i was collected from literatures on randomized controlled trials and was normalized based on the daily UGE data from phase I studies. After normalizing doses, the dose–response relationship of HbA1c reduction of most of SGLT2is was represented by a unified nonlinear mixed-effect model, with the estimated maximum HbA1c (%) reduction (Emax) of 0.796 points, whereas covariate analysis showed that canagliflozin had a 1.33-fold higher Emax than those of the other drugs. Other covariates included baseline HbA1c levels, body weight, disease duration, prior treatment, and renal function. Findings from this study would influence drug selection and adjustment in clinical practice. As with SGLT2is, in cases where the efficacy cannot be easily evaluated but an appropriate pharmacodynamic marker was assessed in early clinical trials, similar approaches for other drug classes can guide strategic and evidence-based dose selection in phase III trials.

Dysregulated renal tubular handling of filtered glucose in patients with type 2 diabetes mellitus: a descriptive study

Objective: To determine the frequency of suspected dysregulated renal tubular handling of filtered glucose, and its association with blood glucose levels in type 2 diabetes mellitus. Method: The analytical, cross-sectional study was conducted from November 2022 to June 2023 at the Department of Medicine along with the Department of Pathology and Biochemistry, Pakistan Railway Hospital, Islamic International Medical College, Rawalpindi, Pakistan, and comprised diabetics aged 19-80 years. Blood and urinary glucose were assessed at the point of contact. Blood glucose 80-180mg/dl was considered glucose in range and >180mg/dl glucose above range. Hyper-function of sodium glucose transport receptors was suspected if urinary glucose was <++ and the function of these receptors was considered normal if urinary sugar was ++ or more. Association of suspected receptors and their association with blood glucose levels was determined. Data was analysed using SPSS 26. Results: Of the 159 diabetics, 91(57%) were females and 68(43%) were males. The overall mean age was 57±11 years (range: 46-68 years). Of the total, 43(27%) patients had glucose in range and 116(73%) had glucose above range. Of the diabetics with glucose above range, 54(47%) patients had hyper-functioning sodium glucose transport receptors, and 62(53%) had normal functioning sodium glucose transport receptors. Of the patients with glucose in range, 11(26%) had hyper-functioning sodium glucose transport receptors, and 32(74%) had normal functioning sodium glucose transport receptors. There was a significant association between sodium glucose transport receptors’ function and blood glucose levels (p<0.001). Conclusion: Dysfunction of sodium glucose transport receptors affected the secretion of glucose in the urine, resulting in impaired glucose regulation in type 2 diabetes mellitus cases. Key Words: Blood glucose, Diabetes, Glycosuria, Sodium-glucose transporter 2.

Familial Renal Glucosuria and Potential Pharmacogenetic Impact on SGLT2 Inhibitors.

Renal glucosuria is a rare inheritable trait caused by loss-of-function variants in the gene that encodes SGLT2 (i.e., SLC5A2). The genetics of renal glucosuria is poorly understood and even less is known on how loss-of-function variants in SLC5A2 may affect response to SGLT2 inhibitors, a new class of medication gaining popularity to treat diabetes by artificially inducing glucosuria. We used two biobanks that link genomic with electronic health record data to study the genetics of renal glucosuria. This included 245,394 participants enrolled in the All of Us (AoU) Research Program and 11,011 enrolled in Marshfield Clinic's Personalized Research Project (PMRP). Association studies in AoU and PMRP identified 10 variants that reached an experiment-wise Bonferroni threshold in either cohort, nine were novel. PMRP was further used as a recruitment source for a prospective SGLT2 pharmacogenetic trial. During a glucose tolerance test, the trial measured urine glucose concentrations in 15 SLC5A2 variant-positive individuals and 15 matched wild types with and without an SGLT2 inhibitor. This trial demonstrated that carriers of SLC5A2 risk variants may be more sensitive to SGLT2 inhibitors compared to wild types (P=0.075). Based on population data, 2% of an ethnically diverse population carry rare variants in SLC5A2 and are at risk for renal glucosuria. As a result, 2% of individuals being treated with SGLT2 inhibitors may respond differently to this new class of medication compared to the general population suggesting a larger investigation into SLC5A2 variants and SGLT2 inhibitors is needed.

Assessment of basic pharmacokinetic parameters of dapagliflozin in TTS formulations in male minipigs

Given the extended time over which diabetes treatment is administered, the transdermal delivery system is anticipated to be a more suitable option for older individuals who may experience difficulty swallowing. The continuous delivery of dapagliflozin and more stable plasma levels are anticipated to reduce the incidence of side effects and the frequency of dosing. The objectives of the study were to determine the safety and plasma pharmacokinetics of dapagliflozin in male minipigs following application of the ointment and skin patch. In the initial phase of the study, the potential for transdermal permeation of dapagliflozin from ointment and transdermal patch to blood plasma of 15 male Göttingen minipigs was investigated. In the subsequent phase, the efficacy of utilising patches of varying strengths and sizes was assessed. The LC/MS method was employed to quantify the concentration of the active substance. The transportation of the studied API to the general circulation and accumulation in tissues were confirmed. The maximum drug concentration (122.99 ng/mL) in plasma was observed on the fourth day of application. The highest calculated Cmax was 131.91 ng/mL with a mean AUC0-last of 6620.7 ng h/mL. Following transdermal administration, dapagliflozin is excreted in the urine. The trend between urinary dapagliflozin 3-O-glucuronide levels and urinary glucose excretion was also observed. The transdermal patch has been demonstrated to be an effective drug delivery system for dapagliflozin.

Non-enzymatic Determination of Glucose in Artificial Urine Using 3D-µPADs through Silver Nanoparticles Formation

Patients with diabetes often experience blood glucose fluctuations, making monitoring crucial. Traditional blood sampling methods pose risks of infection and pain. An alternative non-invasive approach using urine tests has been explored. Recent studies highlight microfluidic paper-based analytical devices (µPADs) as convenient, simple, and easily fabricated tools for non-invasive glucose measurement. This study aims to develop a concept of measuring glucose in artificial urine using 3D-µPADs in a non-enzymatic manner by utilizing glucose as a reducing agent for silver nanoparticle (AgNPs) formation. Embedding three-dimensional connectors in µPADs links the sample and detection zones to limit reagent mixing and improve glucose detection resolution. The optimal conditions were NaOH 10 M, starch 1%, and AgNO3 30 mM, with sample and detection zone volumes of 10 and 9 µL, respectively. The fifth reaction sequence involved AgNO3 in the detection zone and a solution of glucose, NaOH, and starch in the sample zone at 1:1:1 volume ratio. The reagent drying time was 15 min, with immobilization once and reaction time of 9 min. The method showed excellent linearity (R2 = 0.9905), precision (%RSD = 4.27%), accuracy (77.32–92.58%), and limit of detection (11.11 mg/dL).

9237 Loss of Glucose in Urine Reprograms Mitochondrial Function and Increases Mannose Production in the Kidneys to Maintain Adequate Supply of Energy in Renal GLUT2 Knockout Mice

9237 Loss of Glucose in Urine Reprograms Mitochondrial Function and Increases Mannose Production in the Kidneys to Maintain Adequate Supply of Energy in Renal GLUT2 Knockout Mice

Self-Sustaining Triboelectric Nanosensors for Real-Time Urine Analysis in Smart Toilets.

Healthcare has undergone a revolutionary shift with the advent of smart technologies, and smart toilets (STs) are among the innovative inventions offering non-invasive continuous health monitoring. The present technical challenges toward this development include limited sensitivity of integrated sensors, poor stability, slow response and the requirement external energy supply alongside manual sample collection. In this article, triboelectric nanosensor array (TENSA) is introduced featuring electrodes crafted from laser-induced 3D graphene with functional polymers like polystyrene, polyimide, and polycaprolactone for real-time urine analysis while generating 50 volts output via urine droplet-based triboelectrification. Though modulating interfacial double-layer capacitance, these sensors exhibit exceptional sensitivity and selectivity in detecting a broad spectrum of urinary biomarkers, including ions, glucose, and urea with a classification precision of 95% and concentration identification accuracy of up to 0.97 (R2), supported by artificial neural networks. Upon exposure to urine samples containing elevated levels of Na+, K+, and NH4 +, a notable decrease (ranging from 32% to 68%) is observed in output voltages. Conversely, urea induces an increase up to 13%. Experimental validation confirms the stability, robustness, reliability, and reproducibility of TENSA, representing a significant advancement in healthcare technology, offering the potential for improved disease management and prevention strategies.

Cataract as the First Manifestation of Insulin Dependent Diabetes Mellitus

An 8-year-old girl presented with blurry vision. Examination revealed impaired visual acuity (VA) in both eyes and significant lamellar and posterior subcapsular cataracts requiring surgery. Preoperative laboratory tests indicated elevated urine and blood glucose levels, leading to a diagnosis of insulin-dependent diabetes mellitus by a paediatric endocrinologist. She began insulin treatment and underwent lens aspiration with posterior chamber intraocular lens implantation. Postoperatively, her VA improved to 20/30 in the right eye and 20/60 in the left eye.

Sodium-Glucose Cotransporter-2 Inhibitors In Heart Failure

Heart failure (HF) is a serious problem in a modern world, with increasing prevalence among ageing populations. The use of sodium-glucose cotransporter-2 (SGLT2) inhibitors, originally intended to treat type 2 diabetes, has revolutionised the treatment of HF. In this review article, we present the latest evidence on the mechanism of action of SGLT2 inhibitors, also called flosins, in HF. The primary mechanism of action of flosins is to reduce glucose reabsorption from glomerular filtration in the proximal renal tubule with a concomitant reduction in sodium reabsorption, leading to urinary glucose excretion and osmotic diuresis. Based on experimental findings, several pleiotropic effects of SGLT2 inhibitors have been proposed. Mechanisms also include regulation of inflammatory and oxidative pathways along with improved endothelial function. Recent multicentre studies of SGLT2 inhibitors have shown that they reduce hospitalisations for heart failure after their use, regardless of type 2 diabetes and the degree of cardiac systolic dysfunction.

The impact of diabetes on bronchiectasis

Objective: To study the impact of diabetes on bronchiectasis. Methods: From January 1 2017 to December 31 2021, data of 1 310 inpatients with bronchiectasis were retrospectively collected from Shanghai Pulmonary Hospital, Tongji University. This cohort inclueded 78 patients with bronchiectasis and diabetes (bronchiectasis-diabetes group) and 1 232 patients of bronchiectasis without diabetes (simple bronchiectasis group). To mitigate confounding variables, 269 patients with bronchiectasis but without diabetes (bronchiectasis non-diabetes group) were matched with 78 patients of bronchiectasis with diabetes (bronchiectasis-diabetes group) using the propensity score method in a 1∶4 ratio. A comparative analysis of clinical characteristics, laboratory test results, pathogenic infections, and disease severity was performed between the two groups. Analysis of continuous variables was performed using either a t-test or non-parametric test, while categorical data was assessed using the chi-square test. Results: The mean age of individuals in the bronchiectasis-diabetes group (62.99±8.09 years) was significantly higher than that of subjects in the simple bronchiectasis group (57.05±13.07 years) (t=-6.012, P<0.001). After propensity score matching, the pre-albumin level in the bronchiectasis-diabetes group (188.44±71.65 g/L) was found to be lower than in the bronchiectasis non-diabetes group (208.17±62.50 g/L) (t=2.023, P=0.044). In addition, the hospitalization cost for the bronchiectasis-diabetes group [1.59 (1.34, 2.15) Ten thousand yuan] was higher than that in the bronchiectasis non-diabetes group [1.39 (1.23, 1.62) Ten thousand yuan] (U=-3.744, P<0.001).The severity of mMRC in the bronchiectasis-diabetes group was significantly higher than that in the bronchiectasis non-diabetes group (χ2=25.392, P<0.001), and the frequency of previous hospitalization due to aggravation and acute exacerbation within the previous year were higher than in bronchiectasis non-diabetes group (χ2=34.031, 40.841, respectively, P<0.001). In additional, the BSI score was significantly increased in patients with bronchiectasis-diabetes compared to those with bronchiectasis non-diabetes (8.07±4.07 vs. 10.44±3.82) (P<0.001). Furthermore, fasting blood glucose concentration, urine glucose level, and BSI score exhibited positive correlations, whereas pre-albumin concentration showed a negative correlation with the BSI score (all P<0.05). Conclusion: Compared to those without diabetes, patients of bronchiectasis with diabetes have poorer nutritional status, more severe symptoms, increased risk of acute exacerbation, higher BSI score severity, and greater financial burden.

SGLT-2 Inhibitors: The Next-generation Treatment for Type 2 Diabetes Mellitus.

Type 2 diabetes mellitus (T2DM) has become a worldwide concern in recent years, primarily in highly developed Western societies. T2DM causes systemic complications, such as atherosclerotic heart disease, ischemic stroke, peripheral artery disease, kidney failure, and diabetes-related maculopathy and retinopathy. The growing number of T2DM patients and the treatment of long-term T2DM-related complications pressurize and exhaust public healthcare systems. As a result, strategies for combating T2DM and developing novel drugs are critical global public health requirements. Aside from preventive measures, which are still the most effective way to prevent T2DM, novel and highly effective therapies are emerging. In the spotlight of next-generation T2DM treatment, sodium-glucose co-transporter 2 (SGLT-2) inhibitors are promoted as the most efficient perspective therapy. SGLT-2 inhibitors (SGLT2i) include phlorizin derivatives, such as canagliflozin, dapagliflozin, empagliflozin, and ertugliflozin. SGLT-2, along with SGLT-1, is a member of the SGLT family of proteins that play a role in glucose absorption via active transport mediated by Na+/K+ ATPase. SGLT-2 is only found in the kidney, specifically the proximal tubule, and is responsible for more than 90% glucose absorption. Inhibition of SGLT-2 reduces glucose absorption, and consequently increases urinary glucose excretion, decreasing blood glucose levels. Thus, the inhibition of SGLT-2 activity ultimately alleviates T2DM-related symptoms and prevents or delays systemic T2DM-associated chronic complications. This review aimed to provide a more detailed understanding of the effects of SGLT2i responsible for the acute improvement in blood glucose regulation, a prerequisite for T2DM-associated cardiovascular complications control.

Uropathogens and their antibiotic susceptibility patterns among diabetic patients at st. john of god hospital, duayaw nkwanta, Ghana: a cross-sectional study.

Uropathogens are microorganisms that cause urinary tract infections (UTIs). Owing to higher blood glucose levels and compromised immune functions, treatment of uropathogens in diabetic patients is a challenge. This study aims to assess the prevalence of uropathogens and their antibiotic susceptibility among diabetic patients at St. John of God Hospital at Duayaw Nkwanta (SJGHDN) in the Ahafo region of Ghana. The cross-sectional study recruited 175 diabetic patients at SJGHDN between August and September 2023. Questionnaires were used to collect patients' background information. Fasting Blood Sugar (FBS) was assessed by using a glucometer. Urine samples were examined for the presence of uropathogens. A sterile inoculating loop with a calibrated volume of 2 µl was used for plating. Each colony equals 500 CFU/mL. Significant uropathogen was determined by multiplying the counted colonies by 500 to obtain CFU/mL. Positive uropathogen was defined as CFU ≥ 105/mL. Significant uropathogen was defined as ≥200 colonies per sample. The disc diffusion method was used to determine antibiotic susceptibility. Out of the 175 patients, 19.4% expressed various uropathogens with Escherichia coli being the predominant. Suboptimal glucose level was the most significant risk factor (p = 0.038). Glucosuria (p = 0.036), hazy urine (p = 0.028), positive leukocyte esterase (p = 0.001), and pus cells in urine sediment (p = 0.020) were significant indicators of uropathogen occurrence. Klebsiella pneumonia and Proteus mirabilis were resistant to ≥4 antibiotics. Amikacin, nitrofurantoin, levofloxacin, ciprofloxacin, and ceftriaxone demonstrated efficacy against the isolates. This study underscores the notable prevalence of uropathogens in diabetic patients and the alarming levels of antibiotic resistance observed. The results highlight the critical need for vigilant monitoring and customized treatment approaches, particularly for diabetic patients exhibiting risk factors such as elevated urine glucose levels, cloudy urine, and presence of leukocyte esterase and pus cells in urine sediment. The significant resistance to frequently used antibiotics like co-trimoxazole and tetracycline points to the necessity of routine susceptibility testing and the use of alternative antibiotics for effective treatment. These findings can assist healthcare providers in more effectively managing and preventing UTIs in diabetic populations.

Role of Sotagliflozin in Managing Heart Failure in Diabetes

A chronic illness that impairs heart function is heart failure. This malfunction can put strain on other organs and be especially dangerous for those who have long-term conditions like diabetes and high blood pressure. Patients with diabetes are more likely to develop heart failure. Sotagliflozin is an oral medication used to treat diabetes. A dual sodium drug called sotagliflozin shows promise in the treatment of heart failure. An essential new family of medications for the treatment of diabetes is the sodium-dependent glucose transporter 2 (SGLT2) inhibitors. The goal of developing SGLT2 inhibitors has been to achieve high SGLT2 protein selectivity compared to SGLT1 protein. Treating diabetes with a single drug that combines the inhibition of SGLT1 and SGLT2 would offer complementing insulin-independent strategies. Thus, sotagliflozin (LX4211) was created as a dual SGLT1 and SGLT2 inhibitor. Large postprandial glucose decrease, increase of glucagon-like peptide 1, and mild urine glucose excretion are the distinguishing clinical aspects of dual inhibitor of SGLT1 and SGLT2. These characteristics might have an impact on how sotagliflozin is used clinically to treat diabetes.

Non-Enzymatic Detection of Glucose and Ketones in Urine using Paper-Based Analytical Devices

Diabetes, driven by unbalanced diets and unhealthy lifestyles, is highly prevalent. In Indonesia, its prevalence is projected to reach 28.6 million by 2045. Microfluidic paper-based analytical devices (μPADs) are paper-based analytical tools that use hydrophilic paper for measurement and hydrophobic barriers to control fluid flow. This research aims to develop a non-enzymatic method for detecting glucose and ketones in artificial urine using S2Z-μPADs. The fabrication of S2Z-μPADs involves printing the design on Whatman No. 1 paper using wax printing and applying silver nanoparticles for glucose detection and the Schiff base reaction for ketone detection. The results show that the optimum condition for glucose detection is achieved with an AgNO3 concentration of 500 mM. A NaOH concentration of 10 M. Acetoacetate detection is optimized with a glycine concentration of 1 M, sodium nitroprusside concentration of 15%, NaOH concentration of 1 M, a drying time of 8 minutes, and a reaction time of 10 minutes. Validation results demonstrate good linearity for glucose (R² = 0.9821) and ketones (R² = 0.995). High precision was achieved with relative standard deviation (RSD) values of 3.792% for glucose and 1.482% for ketones. The obtained limits of detection (LOD) and limits of quantification (LOQ) indicate that the developed S2Z-μPADs can differentiate between each category of diabetes. The accuracy of glucose and ketone detection ranges from 87.463% to 97.374%. The high accuracy of the μPADs highlights their potential for reliable diabetes management and effective disease monitoring.

Multi-walled carbon nanotubes functionalized with a new Schiff base containing phenylboronic acid residues: applicationtothe development of a bienzymatic glucose biosensor using a response surface methodology approach.

Aninnovative supramolecular architectureis reportedfor bienzymatic glucose biosensing based on the use of a nanohybrid made of multi-walled carbon nanotubes (MWCNTs) non-covalently functionalized with a Schiff base modified with two phenylboronic acid residues (SB-dBA) as platform for the site-specific immobilization of the glycoproteins glucose oxidase (GOx) and horseradish peroxidase (HRP). The analytical signal was obtained from amperometric experiments at - 0.050V in the presence of 5.0 × 10-4M hydroquinone as redox mediator. The concentration of GOx and HRP and the interaction time between the enzymes and the nanohybrid MWCNT-SB-dBA deposited at glassy carbon electrodes (GCEs) were optimized through a central composite design (CCD)/response surface methodology (RSM). The optimal concentrations of GOx and HRP were 3.0mgmL-1 and 1.50mgmL-1, respectively, while the optimum interaction time was 3.0min. The bienzymatic biosensor presented a sensitivity of (24 ± 2) × 102 µA dL mg-1 ((44 ± 4) × 102 µA M-1), a linear range between 0.06mg dL-1 and 21.6mg dL-1 (3.1µM-1.2mM) (R2 = 0.9991),and detection and quantification limits of 0.02mg dL-1 (1.0µM) and 0.06mg dL-1 (3.1µM), respectively. The reproducibility for five sensors prepared with the same MWCNT-SB-dBA nanohybrid was 6.3%, while the reproducibility for sensors prepared with five different nanohybrids and five electrodes each was 7.9%. The GCE/MWCNT-SB-dBA/GOx-HRP was successfully used for the quantification of glucose in artificial human urine and commercial human serum samples.

Fabrication of Glucose Fluorescent Aptasensor Based on CdTe Quantum Dots.

Diabetes is a chronic metabolic disease characterized by high blood glucose (or blood sugar) levels, which harms the heart, blood vessels, eyes, kidneys, and nerves over time. So, it is crucial to regularly control glucose concentration in biological fluids to check its targets, reduce unpleasant symptoms of high and low blood sugar, and avoid long-term diabetes complications. This study developed a simple, rapid, sensitive, and cost-effective fluorescence system for glucose determination. The fluorescent Aptasensor was fabricated using cadmium telluride quantum dots (CdTe QDs) modified with thioglycolic acid and functionalized with thiol-glucose-aptamer through ligand exchange. The thiol-glucose-aptamer interacted directly with CdTe QDs, increasing fluorescence intensity. However, it decreased when the target molecules of glucose were introduced. The structural and morphological characteristics of the Aptasensor were confirmed by various analytical methods such as UV-visible spectroscopy, Fourier-transform infrared spectroscopy (FT-IR), field emission scanning electron microscopy (FESEM), energy dispersive x-ray spectroscopy (EDX), transmission electron microscopy (TEM), atomic force microscopy (AFM), and dynamic light scattering (DLS). According to the typical Stern-Volmer equation, the relationship between fluorescent quenching and target concentration was linear with a detection limit (LOD) of 0.13 ± 1.95 × 10-11 mol L-1 and a relative standard deviation (RSD) of 1.05%. The Aptasensor demonstrated high specificity towards the target and stability over 28 days. Furthermore, it detected glucose in human serum and urine with a recovery rate of up to 99.74%. The results indicate that the fluorescent Aptasensor could be valuable in developing robust sensing technology for low-concentrated analytes.